Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase II, Open Label, Randomized Trial Evaluating the Efficacy and Safety of Complement 5a Receptor Antagonist Avacopan in Crescentic IgA Nephropathy

NCT06676579 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06676579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06676579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase II, Open Label, Randomized Trial Evaluating the Efficacy and Safety of Complement 5a Receptor Antagonist Avacopan in Crescentic IgA Nephropathy
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
June 9, 2025
Completion date
March 31, 2029
Enrollment
16 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy (igan)